| 產(chǎn)品編號(hào) | bs-5001R |
| 英文名稱 | Rabbit Anti-PCK1 antibody |
| 中文名稱 | 磷酸烯醇丙酮酸羧激酶抗體 |
| 別 名 | PCK1; PEPC; GTP; MGC22652; PEP carboxykinase; PEPCK 1; PEPCK1; PEPCKC; Phosphoenolpyruvate carboxykinase 1; Phosphoenolpyruvate carboxylase; Phosphopyruvate carboxylase. |
 |
Specific References (3) | bs-5001R has been referenced in 3 publications.
[IF=5.396] Yuan Liang. et al. Glucocorticoid receptor-mediated alleviation of inflammation by berberine: in vitro, in silico and in vivo investigations. Food Funct. 2021 Oct;: WB ; Human.
[IF=5.279] Tao Wu. et al. Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice. J Agr Food Chem. 2021;XXXX(XXX):XXX-XXX WB ; Rat.
[IF=1.9] Wong, Kayleigh, et al. "Temporal gene expression profiling of the rat knee joint capsule during immobilization-induced joint contractures." BMC Musculoskeletal Disorders 16.1 (2015): 125. IHC-P ; Rat.
|
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 激酶和磷酸酶 |
| 抗體來源 | Rabbit |
| 克隆類型 | Polyclonal |
| 交叉反應(yīng) | (predicted: Human,Mouse,Rat,Rabbit,Pig,Cow,Dog,Horse) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000,ELISA=1:5000-10000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 69kDa |
| 細(xì)胞定位 | 細(xì)胞漿 |
| 性 狀 | Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human PEPC: 461-560/622 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 0.01M TBS (pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項(xiàng) | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
PCK1 is a main control point for the regulation of gluconeogenesis. This cytosolic enzyme, along with GTP, catalyzes the formation of phosphoenolpyruvate from oxaloacetate, with the release of carbon dioxide and GDP. The expression of the corresponding gene can be regulated by insulin, glucocorticoids, glucagon, cAMP, and diet. A mitochondrial isozyme has also been characterized. Function: Catalyzes the conversion of oxaloacetate (OAA) to phosphoenolpyruvate (PEP), the rate-limiting step in the metabolic pathway that produces glucose from lactate and other precursors derived from the citric acid cycle. Subunit: Monomer. Subcellular Location: Cytoplasm. Tissue Specificity: Major sites of expression are liver, kidney and adipocytes. Post-translational modifications: Acetylation is increased on addition of glucose and appears to regulate the protein stability. DISEASE: Defects in PCK1 are the cause of cytosolic phosphoenolpyruvate carboxykinase deficiency (C-PEPCKD) [MIM:261680]. A metabolic disorder resulting from impaired gluconeogenesis. It is a rare disease with less than 10 cases reported in the literature. Clinical characteristics include hypotonia, hepatomegaly, failure to thrive, lactic acidosis and hypoglycemia. Autoposy reveals fatty infiltration of both the liver and kidneys. The disorder is transmitted as an autosomal recessive trait. Similarity: Belongs to the phosphoenolpyruvate carboxykinase [GTP] family. SWISS: P35558 Gene ID: 5105 Database links: Entrez Gene: 5105 Human Entrez Gene: 18534 Mouse Omim: 614168 Human SwissProt: P35558 Human SwissProt: Q9Z2V4 Mouse |
